Cellular Immunotherapy Market Size - Share Outlook, Growth Analysis Report and Forecast Trends 2026-2030

Cellular immunotherapy involves collecting, modifying, and reinfusing a patient's or donor's immune cells to target disease, with chimeric antigen receptor T-cell (CAR-T) therapy being the most commercially advanced form. The global market was estimated at about $9.35 billion in 2025 and is projected to grow at a compound annual rate near 15.4%, reaching tens of billions of dollars by the early 2030s. North America currently leads on the back of FDA approvals, reimbursement frameworks, and a dense biotech ecosystem, while Asia-Pacific is the fastest-growing region as China, Japan, and South Korea scale out domestic CAR-T manufacturing.

• •Estimated global value of approximately $9.35 billion in 2025.
• •Forecast compound annual growth rate of about 15.4%.
• •North America leads in revenue; Asia-Pacific is the fastest-growing region.

Rising global cancer incidence is the principal clinical driver, as cellular therapies address hematologic malignancies with high unmet need. Regulatory momentum, including multiple FDA and EMA approvals of CAR-T products since 2017, has lowered development risk and encouraged capital deployment into next-generation platforms such as allogeneic, NK-cell, and TCR-based therapies. Expanding reimbursement coverage in the United States and Europe has made high list-price therapies commercially viable, while improving manufacturing automation is gradually reducing per-patient cost.

• •Growing cancer prevalence and unmet need in refractory disease.
• •Increasing regulatory approvals for autologous and allogeneic cell therapies.
• •Expanding reimbursement and improvements in scalable manufacturing.

By therapy type, the market is dominated by CAR-T-cell therapies, followed by natural killer (NK) cell therapies, T-cell receptor (TCR) therapies, tumor-infiltrating lymphocyte (TIL) therapies, and dendritic cell vaccines such as sipuleucel-T. By indication, multiple myeloma, diffuse large B-cell lymphoma, and other B-cell malignancies account for the bulk of revenue today, with solid-tumor applications representing the major future opportunity. Geographically, the United States holds the largest share, supported by clinical trial activity and approved products, while Europe contributes steady mid-teens growth and Asia-Pacific is accelerating through local approvals and capacity build-out.

• •CAR-T leads by therapy type; NK, TCR, TIL, and dendritic cell therapies are emerging.
• •Hematologic cancers dominate revenue today; solid tumors are the next frontier.
• •United States is the largest market, with Europe and Asia-Pacific as key growth regions.

What are the recent trends and outlook?

Allogeneic, off-the-shelf cell therapies are advancing through clinical trials and are widely viewed as the next step toward lower-cost, scalable treatment. Gene-editing tools such as CRISPR and base editing are being integrated into both autologous and allogeneic programs to improve persistence, safety, and targeting. Manufacturing is shifting toward decentralized, automated, and closed-system platforms to shorten vein-to-vein time and address the logistical constraints that have historically limited patient access.

• •Move toward allogeneic, off-the-shelf therapies to reduce cost and turnaround time.
• •Integration of gene editing (CRISPR, base, prime editing) into next-generation cell therapies.
• •Investment in automated, decentralized manufacturing to scale patient access.